These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38532078)

  • 21. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
    Lin TL; Rizzieri DA; Ryan DH; Schiller GJ; Kolitz JE; Uy GL; Hogge DE; Solomon SR; Wieduwilt MJ; Ryan RJ; Faderl S; Cortes JE; Lancet JE
    Blood Adv; 2021 Mar; 5(6):1719-1728. PubMed ID: 33724305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.
    Feldman EJ; Kolitz JE; Trang JM; Liboiron BD; Swenson CE; Chiarella MT; Mayer LD; Louie AC; Lancet JE
    Leuk Res; 2012 Oct; 36(10):1283-9. PubMed ID: 22840315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
    Kolitz JE; Strickland SA; Cortes JE; Hogge D; Lancet JE; Goldberg SL; Villa KF; Ryan RJ; Chiarella M; Louie AC; Ritchie EK; Stuart RK
    Leuk Lymphoma; 2020 Mar; 61(3):631-640. PubMed ID: 31760835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CPX-351 (vyxeos) in AML.
    Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
    Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
    Lemoli RM; Montesinos P; Jain A
    Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
    Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
    Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
    Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
    Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
    Mehta P; Campbell V; Maddox J; Floisand Y; Kalakonda AJM; O'Nions J; Coats T; Nagumantry S; Hodgson K; Whitmill R; Amott I; Flynn G; Taussig D; Zhao R; Cunningham N; Roset M; Cuadras D; Medalla G; Kuter H; Park S; Legg A; Khan AB
    Br J Haematol; 2024 Oct; 205(4):1326-1336. PubMed ID: 38977430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals.
    Wang Q; Tardi P; Sadowski N; Xie S; Heller D; Mayer L
    Nanomedicine; 2020 Nov; 30():102275. PubMed ID: 32750494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
    Villa KF; Ryan RJ; Chiarella M; Louie AC
    J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
    Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
    Cancer; 2001 Jul; 92(1):7-14. PubMed ID: 11443603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
    Chiche E; Rahmé R; Bertoli S; Dumas PY; Micol JB; Hicheri Y; Pasquier F; Peterlin P; Chevallier P; Thomas X; Loschi M; Genthon A; Legrand O; Mohty M; Raffoux E; Auberger P; Caulier A; Joris M; Bonmati C; Roth-Guepin G; Lejeune C; Pigneux A; Vey N; Recher C; Ades L; Cluzeau T
    Blood Adv; 2021 Jan; 5(1):176-184. PubMed ID: 33570629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
    Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
    Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.